Stefanie Grund

Title: Stefanie Grund: Innovator in Artificial Nucleic Acids

Introduction

Stefanie Grund is a prominent inventor based in Stuttgart, Germany. She has made significant contributions to the field of biotechnology, particularly in the development of artificial nucleic acid molecules. With a total of 7 patents to her name, her work has the potential to revolutionize gene therapy and genetic vaccination.

Latest Patents

Among her latest patents, one notable invention involves artificial nucleic acid molecules designed to improve protein expression. This invention relates to a method for stimulating an immune response through the intramuscular injection of an artificial nucleic acid molecule. This molecule comprises an open reading frame encoding an antigen and a 3'-UTR with at least two poly(A) sequences. The method aims to enhance the immune response to the antigen or increase the neutralizing antibody response. Another significant patent focuses on an artificial nucleic acid molecule that includes at least one open reading frame and at least one untranslated region element. This invention is characterized by high translation efficiency, which is crucial for effective gene therapy and genetic vaccination.

Career Highlights

Stefanie has worked with notable companies in the biotechnology sector, including CureVac SE and CureVac AG. Her experience in these organizations has allowed her to collaborate on groundbreaking research and development projects.

Collaborations

Throughout her career, Stefanie has collaborated with esteemed colleagues such as Thomas Schlake and Andreas Thess. These partnerships have contributed to her innovative work and the advancement of her inventions.

Conclusion

Stefanie Grund is a trailblazer in the field of artificial nucleic acids, with a focus on enhancing immune responses and translation efficiency. Her contributions are paving the way for advancements in gene therapy and genetic vaccination.